Advanced search
2 files | 979.79 KB

Vaccination of mice using the West Nile virus E-protein in a DNA prime-protein boost strategy stimulates cell-mediated immunity and protects mice against a lethal challenge

(2014) PLOS ONE. 9(2).
Author
Organization
Abstract
West Nile virus (WNV) is a mosquito-borne flavivirus that is endemic in Africa, the Middle East, Europe and the United States. There is currently no antiviral treatment or human vaccine available to treat or prevent WNV infection. DNA plasmid-based vaccines represent a new approach for controlling infectious diseases. In rodents, DNA vaccines have been shown to induce B cell and cytotoxic T cell responses and protect against a wide range of infections. In this study, we formulated a plasmid DNA vector expressing the ectodomain of the E-protein of WNV into nanoparticles by using linear polyethyleneimine (lPEI) covalently bound to mannose and examined the potential of this vaccine to protect against lethal WNV infection in mice. Mice were immunized twice (prime - boost regime) with the WNV DNA vaccine formulated with lPEI-mannose using different administration routes (intramuscular, intradermal and topical). In parallel a heterologous boost with purified recombinant WNV envelope (E) protein was evaluated. While no significant E-protein specific humoral response was generated after DNA immunization, protein boosting of DNA-primed mice resulted in a marked increase in total neutralizing antibody titer. In addition, E-specific IL-4 T-cell immune responses were detected by ELISPOT after protein boost and CD8(+) specific IFN-gamma expression was observed by flow cytometry. Challenge experiments using the heterologous immunization regime revealed protective immunity to homologous and virulent WNV infection.
Keywords
DOMAIN-III, RESPONSES, UNITED-STATES, CLINICAL-TRIALS, ENVELOPE PROTEIN, NEUTRALIZING ANTIBODIES, T-CELL, IN-VITRO, GENE DELIVERY, DENDRITIC CELLS

Downloads

  • De Filette et al. PlosOne.pdf
    • full text
    • |
    • open access
    • |
    • PDF
    • |
    • 877.52 KB
  • De Filette 2014 PO corr.pdf
    • full text
    • |
    • open access
    • |
    • PDF
    • |
    • 102.27 KB

Citation

Please use this url to cite or link to this publication:

Chicago
De Filette, Marina, Silke Soehle, Sebastian Ulbert, Justin Richner, Michael S Diamond, Alessandro Sinigaglia, Luisa Barzon, et al. 2014. “Vaccination of Mice Using the West Nile Virus E-protein in a DNA Prime-protein Boost Strategy Stimulates Cell-mediated Immunity and Protects Mice Against a Lethal Challenge.” Plos One 9 (2).
APA
De Filette, M., Soehle, S., Ulbert, S., Richner, J., Diamond, M. S., Sinigaglia, A., Barzon, L., et al. (2014). Vaccination of mice using the West Nile virus E-protein in a DNA prime-protein boost strategy stimulates cell-mediated immunity and protects mice against a lethal challenge. PLOS ONE, 9(2).
Vancouver
1.
De Filette M, Soehle S, Ulbert S, Richner J, Diamond MS, Sinigaglia A, et al. Vaccination of mice using the West Nile virus E-protein in a DNA prime-protein boost strategy stimulates cell-mediated immunity and protects mice against a lethal challenge. PLOS ONE. 2014;9(2).
MLA
De Filette, Marina, Silke Soehle, Sebastian Ulbert, et al. “Vaccination of Mice Using the West Nile Virus E-protein in a DNA Prime-protein Boost Strategy Stimulates Cell-mediated Immunity and Protects Mice Against a Lethal Challenge.” PLOS ONE 9.2 (2014): n. pag. Print.
@article{6839374,
  abstract     = {West Nile virus (WNV) is a mosquito-borne flavivirus that is endemic in Africa, the Middle East, Europe and the United States. There is currently no antiviral treatment or human vaccine available to treat or prevent WNV infection. DNA plasmid-based vaccines represent a new approach for controlling infectious diseases. In rodents, DNA vaccines have been shown to induce B cell and cytotoxic T cell responses and protect against a wide range of infections. In this study, we formulated a plasmid DNA vector expressing the ectodomain of the E-protein of WNV into nanoparticles by using linear polyethyleneimine (lPEI) covalently bound to mannose and examined the potential of this vaccine to protect against lethal WNV infection in mice. Mice were immunized twice (prime - boost regime) with the WNV DNA vaccine formulated with lPEI-mannose using different administration routes (intramuscular, intradermal and topical). In parallel a heterologous boost with purified recombinant WNV envelope (E) protein was evaluated. While no significant E-protein specific humoral response was generated after DNA immunization, protein boosting of DNA-primed mice resulted in a marked increase in total neutralizing antibody titer. In addition, E-specific IL-4 T-cell immune responses were detected by ELISPOT after protein boost and CD8(+) specific IFN-gamma expression was observed by flow cytometry. Challenge experiments using the heterologous immunization regime revealed protective immunity to homologous and virulent WNV infection.},
  articleno    = {e87837},
  author       = {De Filette, Marina and Soehle, Silke and Ulbert, Sebastian and Richner, Justin and Diamond, Michael S and Sinigaglia, Alessandro and Barzon, Luisa and Roels, Stefan and Lisziewicz, Julianna and Lorincz, Orsolya and Sanders, Niek},
  issn         = {1932-6203},
  journal      = {PLOS ONE},
  language     = {eng},
  number       = {2},
  pages        = {10},
  title        = {Vaccination of mice using the West Nile virus E-protein in a DNA prime-protein boost strategy stimulates cell-mediated immunity and protects mice against a lethal challenge},
  url          = {http://dx.doi.org/10.1371/journal.pone.0087837},
  volume       = {9},
  year         = {2014},
}

Altmetric
View in Altmetric
Web of Science
Times cited: